Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease

Yasunari Takada, Koichi Matsuo

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Gefitinib is an anticancer drug developed to inhibit the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Two structurally-related EGFR tyrosine kinase inhibitors, gefitinib (Iressa) and erlotinib (Tarceva), are used as oral chemotherapy by patients with non-small-cell lung cancer. Immediately after introduction of gefitinib to clinical practice, interstitial lung disease was identified as a life-threatening adverse effect, although this condition can be well managed. It is still unclear whether gefitinib and other EGFR inhibitors induce similar adverse effects in lung. We previously established mouse models of interstitial lung disease in which gefitinib induces expression of Fosl1 (which encodes the AP-1 transcription factor Fra-1) in the presence of exogenous or endogenous Toll-like receptor ligands, leading to abnormal cytokine and chemokine expression. Here, we compared and monitored the effects of EGFR inhibitors gefitinib, erlotinib and AG1517 (PD153035) on the mRNA expression levels of Fosl1, Tnf and Ccl2. Unexpectedly, gefitinib, but not the other tyrosine kinase inhibitors, elicited the Fosl1 expression profile proposed to be predictive of interstitial lung disease, suggesting that gefitinib-induced interstitial lung disease is an off-target effect not elicited by erlotinib.

Original languageEnglish
Pages (from-to)120-127
Number of pages8
JournalKeio Journal of Medicine
Volume61
Issue number4
DOIs
Publication statusPublished - 2012 Dec 1

Keywords

  • EGFR inhibitor
  • Erlotinib
  • Gefitinib
  • Interstitial lung disease

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease'. Together they form a unique fingerprint.

Cite this